Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS receives R10 million in student funding from Absa
2017-06-19

 

Description: UFS receives R10 million in student funding from Absa Tags: UFS receives R10 million in student funding from Absa

From the left: Asive Dlanjwa (UFS SRC) Prof Francis Petersen, Fikemini Dlamini,
Bertie Smith and Lesley Afrika (student beneficiary 2016-2017)

 

In support of building a more equitable and prosperous Africa, and in response to the plight of students who lack financial aid at universities across the country, Absa Bank handed over a cheque of R10 million to the University of the Free State (UFS) at a ceremony held on the Bloemfontein Campus on 13 June 2017 by the office of Institutional Advancement. The allocation of these funds will assist students who meet the bursary programme criteria (proven financial need, students who are from households with a combined income of less than R1 million per annum, with an academic average of 55% or higher).

Corporate and higher education collaborate
Speaking at the event, Rector and Vice-Chancellor of the UFS Prof Francis Petersen highlighted the important role corporates play in collaborating with educational institutions to help support future professionals who are the future builders of the economy and will later lead industry. “Absa and the UFS enjoy a good relationship and it is our hope that this bursary programme will grow from strength to strength,” he said.

In 2016 alone, Absa Bank disbursed R12 million towards settling outstanding fees for 439 students in four faculties of the UFS. In 2017 the funds will be allocated similarly to cover financial needs of qualifying students. Mr Bertie Smith, Absa Management Executive: Central Region said: “The university plays an important role in building future leaders and Absa’s strategy of shared growth supports the focus on education.”

Responding to a greater socioeconomic need
The event was attended by staff of the UFS and delegates from the Absa group, as well as students who were beneficiaries of the Absa Bursary Fund in 2016. Mr Fikemini Dlamini, Absa Head: Public Sector Business Banking, said the bursary programme was born out of the growing need to fund and develop the education of young people, and is a response to the outcry from students across the country in the “Fees Must Fall” movement. He said: “Educating one young person has a knock-on effect that has the potential to alleviate poverty in many families and communities around us.”



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept